

DEPRENYL INC., DELAWARE, USA

Balance Sheet as at 31 March,	Note No.	2016		2015	
		USD	₹ in 000's	USD	₹ in 000's
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share Capital	1	15	1	15	1
Reserves and Surplus	2	3,122,735	206,880	3,021,281	188,829
		3,122,750	206,881	3,021,296	188,830
Non-current liabilities					
Deferred tax liabilities(Net)	3	459,000	30,409	459,000	28,688
		459,000	30,409	459,000	28,688
Current liabilities					
Other Current liabilities	4	282,517	18,717	282,284	17,643
		282,517	18,717	282,284	17,643
Total		3,864,267	256,007	3,762,580	235,161
II. ASSETS					
Non-current assets					
Fixed Assets					
Intangible Assets					
Long-term loans and advances	5	1,350,000	89,438	1,350,000	84,375
		20,250	1,342	20,250	1,266
		1,370,250	90,780	1,370,250	85,641
Current Assets					
Cash and Cash equivalents	6	34,334	2,274	34,324	2,145
Short-term loans and advances	7	2,459,683	162,953	2,358,006	147,375
		2,494,017	165,227	2,392,330	149,520
Total		3,864,267	256,007	3,762,580	235,161

PRAKASH C BISHT
CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida
Date : 18 May 2016

DEPRENYL INC., DELAWARE, USA

Statement of Profit and Loss for the year ended 31 March,	Note No.	2016		2015	
		USD	₹ in 000's	USD	₹ in 000's
REVENUE					
Revenue from operations(net)	8	-	-	31,388	1,930
Other Income	9	101,679	6,648	101,419	6,203
Total Revenue		101,679	6,648	132,807	8,133
EXPENSES					
Other expenses	10	225	15	-	-
Total Expenses		225	15	-	-
Profit Before Tax		101,454	6,633	132,807	8,133
Tax expenses:					
- Current Tax		-	-	78,255	4,858
Profit for the year		101,454	6,633	54,552	3,275

PRAKASH C BISHT
CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida
Date : 18 May 2016

DEPRENYL INC., DELAWARE, USA

Cash flow statement for the year ended 31 March,	2016		2015	
	USD	₹ in 000's	USD	₹ in 000's
A. Cash Flow arising from Operating Activities :				
Net profit before tax	101,454	6,633	132,807	8,133
Adjustments for:				
Interest Income	(101,676)	(6,631)	(101,419)	(6,202)
Operating Profit before Working Capital Changes	(222)	2	31,388	1,931
Adjustments for :				
Increase/(Decrease) in Current Liabilities	225	15	(5,310)	(324)
Cash generated from Operations	3	17	26,078	1,607
Net Cash Inflow/(Outflow) in course of Operating Activities	3	17	26,078	1,607
B. Cash Flow arising from Investing Activities :				
Interest Received	7	0	34	2
Net Cash Inflow/(Outflow) in course of Investing Activities	7	0	34	2
C. Foreign Currency Translation Difference arising on Conversion		113		44
Net Increase in Cash & Cash equivalents (A+B+C)	10	129	26,112	1,653
Add: Cash and Cash Equivalents at the beginning of Year	34,324	2,145	8,212	492
Cash and Cash Equivalents at the end of the Year	34,334	2,274	34,324	2,145
<p>Note: Cash flow statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".</p>				

PRAKASH C BISHT
CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida
Date : 18 May 2016

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31 March,	2016		2015	
	USD	₹ in 000's	USD	₹ in 000's
1. SHARE CAPITAL				
Authorized				
3000 Equity Shares of USD 0.01 each	30		30	
	30		30	
Issued, Subscribed and Paid up				
1500 Equity Shares of USD 0.01 each	15	1	15	1
(Previous year 1500 Equity Shares of USD 0.01 each)				
	15	1	15	1

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 0.01. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

1.3) The details of shareholders holding more than 5% shares as at 31 March, 2016 and 31 March, 2015 is set out below:

Name of the shareholder	No. of shares	% holding in the class	No. of shares	% holding in the class
Draximage Ltd., Cyprus, Holding Company	1500	100%	1,500	100%

1.4) The reconciliation of the number of shares outstanding as at 31 March, 2016 and 31 March, 2015 is set out below:

Particulars	As at 31 March 2016		As at 31 March 2015	
	No. of shares	₹ in 000's	No. of shares	₹ in 000's
Numbers of shares at the beginning	1,500	1	1,500	1
Add: Shares issued during the year	-	-	-	-
Numbers of shares at the end	1,500	1	1,500	1

1.5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by its holding company/ultimate holding company and/or their subsidiaries/associates are as below:

Particulars	As at 31 March 2016		As at 31 March 2015	
	No. of shares	₹ in 000's	No. of shares	₹ in 000's
Draximage Ltd., Cyprus, Holding Company	1,500	1	1,500	1

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31 March,	2016		2015	
	USD	₹ in 000's	USD	₹ in 000's
2 RESERVES AND SURPLUS				
Securities Premium Account				
Opening Balance	1,400,085	69,892	1,400,085	69,892
Add: Premium on shares issued during the year	-	-	-	-
	1,400,085	69,892	1,400,085	69,892
Foreign Currency Translation Reserve				
Opening Balance	-	48,664	-	40,847
Add/(Less): Effect of foreign exchange rate variation during the year	-	11,418	-	7,817
Closing Balance	-	60,082	-	48,664
Surplus/(Deficit)				
Opening Balance	1,621,196	70,273	1,566,644	66,998
Add: Net Profit / (Deficit) for the year transferred from Statement of Profit and Loss	101,454	6,633	54,552	3,275
	1,722,650	76,906	1,621,196	70,273
TOTAL	3,122,735	206,880	3,021,281	188,829
3 DEFERRED TAX LIABILITY (NET)				
Deferred Tax Liabilities	459,000	30,409	459,000	28,688
Deferred Tax Assets	-	-	-	-
Deferred Tax Liabilities(Net)	459,000	30,409	459,000	28,688
4 OTHER CURRENT LIABILITIES				
Other Payables	282,517	18,717	282,284	17,643
	282,517	18,717	282,284	17,643

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31 March,	2016		2015	
	USD	₹ in 000's	USD	₹ in 000's
5. LONG TERM LOANS AND ADVANCES				
Advance payment of income tax	20,250	1,342	20,250	1,266
	20,250	1,342	20,250	1,266
6. CASH AND CASH EQUIVALENTS				
Balances with banks:				
- In Current Accounts	34,334	2,274	34,324	2,145
	34,334	2,274	34,324	2,145
7. SHORT TERM LOANS AND ADVANCES				
Loans and advances to related parties(unsecured,considered good)	2,000,000	132,500	2,000,000	125,000
Advance recoverable in cash and kind				
- From related parties	459,683	30,453	358,006	22,375
	2,459,683	162,953	2,358,006	147,375

DEPRENYL INC., DELAWARE, USA

Notes to the financial statements for the year ended 31 March,	2016		2015	
	USD	₹ in 000's	USD	₹ in 000's
8. REVENUE FROM OPERATIONS				
Royalty Income	-	-	31,388	1,930
	-	-	31,388	1,930
9. OTHER INCOME				
Interest Income	101,679	6,648	101,419	6,203
	101,679	6,648	101,419	6,203
10. OTHER EXPENSES				
Legal , Professional and Consultancy Charges	225	15	-	-
	225	15	-	-